Business
Medicure Q1 Results and Conference Call Dates
Medicure Q1 Results and Conference Call Dates Canada NewsWire WINNIPEG, May 18, ...
About this update from Medicure Inc.
[{"type":"text","content":"\n\n\n\nMedicure Q1 Results and Conference Call Dates\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nWINNIPEG, May 18, 2017\n\n\n\nWINNIPEG, May 18, 2017 /CNW/ - Medicure Inc. (\"Medicure\") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will release financial results for the first quarter after market close on Wednesday, May 24, 2017. Medicure will hold a conference call and webcast regarding the results on Thursday, May 25, 2017 at 7:30 AM Central Time (8:30 AM Eastern Time).\n\nConference Call Info:\n\nTopic:  Medicure's Q1 Results\n\nCall date:  Thursday, May 25, 2017\n\nTime:  7:30 AM Central Time (8:30 AM Eastern Time)\n\nCanada toll-free:  1 (888) 465-5079   Canada toll: 1 (416) 216-4169\n\nUnited States toll-free:  1 (888) 545-0687\n\nPasscode:  8196 147#            \n\nWebcast:  This conference call will be webcast live over the internet and can be accessed from the Medicure investor relations page at the following link: http://www.medicure.com/investors.html  \n\nYou may request international country-specific access information by e-mailing the Company in advance. Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event at the Company's website.\n\nAbout Medicure Inc.\n\nMedicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market. The primary focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) in the United States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc. Additionally, Medicure holds a majority interest in Apicore. For more information on Medicure please visit www.medicure.com. \n\nAbout Apicore\n\nApicore is a private, New Jersey based developer and manufacturer of specialty Active Pharmaceutical ...